• Le 15 septembre 2022
    IRS-UN & Webinar
    false false

Seminar by Richard Tomasini, group leader of the "Microenvironment and inter-cellular dialogue", "Pancreatic Cancer" Team at Cancer Research Center of Marseille

Pancreatic cancer (mainly pancreatic ductal adenocarcinoma, PDA) represents the fourth leading cause of cancer-related death in western countries and is projected to become the second by 2030. With an overall 5-year survival rate at only ~8% and a median survival rate of 6 months, PDA figures as one of the solid cancers with the worst prognosis, together with a late diagnosis, a rapid progression towards advancing stages of the disease, a lack of biomarkers and the prevalence of therapeutic resistance. Thus, clinicians are confronted with advanced and aggressive tumors with few therapeutic options, highlighting the urgent need to better understand the molecular mechanisms underlying pancreatic cancer carcinogenesis and therapeutic resistance in order to design new clinical tools to improve patients’ management.

The former vision of PDA led to the substantial development of therapeutic tools focused on cancer cell targeting, neglecting the impact of the stromal compartment, which could explain the rather limited improvement in patients’ survival over the last 20 years. This suggests that much more is needed to be discovered on the functional relationship between the various cell types composing PDA before integrating and subsequently transforming this knowledge into clinical tools to improve patient care. In the last 10 years, our group focused on deciphering the inter-cellular dialogue between stromal and cancer cells and its consequent impact on PDA carcinogenesis, physiology and resistance to treatment. At present centered on extracellular vesicles-based crosstalk, we are evaluating their role on immune cells differentiation, therapeutic resistance and matrix remodeling.